Gastrointestinal Stromal Tumor Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

Description

Gastrointestinal stromal tumors (GISTs) have long posed significant challenges in the realm of oncology. However, a recent groundbreaking study has shed light on the remarkable progress made in understanding, awareness, and treatment options for this prevalent mesenchymal tumor.

Understanding the Landscape:

GISTs, recognized as one of the most common mesenchymal tumors worldwide, have an estimated incidence rate of 14.5 per million individuals, with a prevalence of 129 cases per million in the United States alone. Despite accounting for less than one percent of all gastrointestinal tract tumors globally, the impact of GISTs on patient health and healthcare systems cannot be underestimated.

Projections for Market Growth:

According to an exclusive study conducted by Fairfield Market Research, the global market for gastrointestinal stromal tumors is set to skyrocket, surpassing US$ 1.2 billion in 2024. With a robust compound annual growth rate (CAGR) of 7.6% projected during the forecast period (2024-2031), this market surge signifies a momentous stride towards addressing the challenges posed by GISTs.

Stomach Indications Spearhead Revenue Generation:

While GISTs can appear in various parts of the gastrointestinal tract, the stomach stands out as the primary site for tumor occurrence. A significant portion of revenues in the global gastrointestinal stromal tumor market is linked to stomach indications, emphasizing the pressing need to address this widespread concern.

Hospitals Take Center Stage:

With advancements in clinical practices, hospitals have become the focal point for treating GISTs. The extended post-treatment hospitalization period, alongside the high morbidity associated with GISTs, emphasizes the crucial role of hospitals as the primary end-users in the global gastrointestinal stromal tumor market. Looking ahead, hospitals are anticipated to generate substantial revenues from GIST treatments by 2031, highlighting the necessity for comprehensive care facilities.

With advancements in clinical practices, hospitals have become the primary hub for treating GISTs. The extended post-treatment hospital stay, along with the significant morbidity linked with GISTs, highlights the crucial role hospitals play as the predominant end-users in the global gastrointestinal stromal tumor market. Looking ahead, hospitals are anticipated to yield substantial revenues from GIST treatments by 2031, emphasizing the necessity for comprehensive care facilities.

Chemotherapy: A Cornerstone in GIST Treatment:

The multidisciplinary nature of GIST treatment necessitates the collaboration of various medical specialties. Chemotherapy remains a sought-after treatment modality, particularly for inoperable cases. Over the forecast period, chemotherapy for GISTs is anticipated to witness a significant revenue surge.

Key Players Driving Market Expansion:

Leading pharmaceutical companies and medical device manufacturers, including Novartis AG, Sun Pharmaceutical Industries Limited, Pfizer Inc., Bayer Aktiengesellschaft, and NATCO Pharma Limited, are at the forefront of advancing GIST treatments. Despite a competitive landscape dominated by a handful of companies, their relentless efforts are poised to propel the global gastrointestinal stromal tumor market towards unprecedented growth by 2031.

North America Leads the Charge:

With a burgeoning market for GIST treatments, North America is anticipated to represent the largest share of the global market by 2031. Unhealthy dietary habits, increasing use of food additives, and the prevalence of genetic disorders are cited as key drivers fueling market growth in the region. A projected CAGR of 6.9% during the forecast period underscores the region's pivotal role in shaping the trajectory of the gastrointestinal stromal tumor market.

Market Segmentation:

The global gastrointestinal stromal tumor market has been meticulously segmented based on regions, including North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan, and Middle East and Africa. Furthermore, the report provides country-specific forecasts to facilitate comprehensive analysis. Additionally, segmentation based on indication, end-use, and treatment modalities offers valuable insights into the diverse facets of the global market landscape.

On the basis of indication

Stomach
Small Intestine
Others

key end-users

Hospitals
Clinics
Specialized Cancer Treatment Centers
Other End Users

Gastrointestinal stromal

Targeted Drug Therapy
Chemotherapy
Radiation Therapy
Surgery
Other Therapies

1. Executive Summary

1.1. Global Gastrointestinal Stromal Tumor Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Gastrointestinal Stromal Tumor Market Outlook, 2018 - 2031

3.1. Global Gastrointestinal Stromal Tumor Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Stomach
  - 3.1.1.2. Small Intestine
  - 3.1.1.3. Others
3.2. Global Gastrointestinal Stromal Tumor Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Targeted Drug Therapy
  - 3.2.1.2. Chemotherapy
  - 3.2.1.3. Radiation Therapy
  - 3.2.1.4. Surgery
  - 3.2.1.5. Other Therapies
3.3. Global Gastrointestinal Stromal Tumor Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Hospitals
  - 3.3.1.2. Clinics
  - 3.3.1.3. Specialized Cancer Treatment Centers
  - 3.3.1.4. Other End Users
3.4. Global Gastrointestinal Stromal Tumor Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. North America
  - 3.4.1.2. Europe
  - 3.4.1.3. Asia Pacific
  - 3.4.1.4. Latin America
  - 3.4.1.5. Middle East & Africa

4. North America Gastrointestinal Stromal Tumor Market Outlook, 2018 - 2031

4.1. North America Gastrointestinal Stromal Tumor Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Stomach
  - 4.1.1.2. Small Intestine
  - 4.1.1.3. Others
4.2. North America Gastrointestinal Stromal Tumor Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Targeted Drug Therapy
  - 4.2.1.2. Chemotherapy
  - 4.2.1.3. Radiation Therapy
  - 4.2.1.4. Surgery
  - 4.2.1.5. Other Therapies
4.3. North America Gastrointestinal Stromal Tumor Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Hospitals
  - 4.3.1.2. Clinics
  - 4.3.1.3. Specialized Cancer Treatment Centers
  - 4.3.1.4. Other End Users
4.4. North America Gastrointestinal Stromal Tumor Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. U.S. Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 4.4.1.2. U.S. Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 4.4.1.3. U.S. Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 4.4.1.4. Canada Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 4.4.1.5. Canada Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 4.4.1.6. Canada Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
- 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Gastrointestinal Stromal Tumor Market Outlook, 2018 - 2031

5.1. Europe Gastrointestinal Stromal Tumor Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Stomach
  - 5.1.1.2. Small Intestine
  - 5.1.1.3. Others
5.2. Europe Gastrointestinal Stromal Tumor Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Targeted Drug Therapy
  - 5.2.1.2. Chemotherapy
  - 5.2.1.3. Radiation Therapy
  - 5.2.1.4. Surgery
  - 5.2.1.5. Other Therapies
5.3. Europe Gastrointestinal Stromal Tumor Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Hospitals
  - 5.3.1.2. Clinics
  - 5.3.1.3. Specialized Cancer Treatment Centers
  - 5.3.1.4. Other End Users
5.4. Europe Gastrointestinal Stromal Tumor Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Germany Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.2. Germany Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.3. Germany Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.4. U.K. Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.5. U.K. Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.6. U.K. Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.7. France Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.8. France Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.9. France Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.10. Italy Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.11. Italy Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.12. Italy Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.13. Turkey Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.14. Turkey Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.15. Turkey Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.16. Russia Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.17. Russia Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.18. Russia Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.19. Rest of Europe Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 5.4.1.20. Rest of Europe Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.21. Rest of Europe Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Gastrointestinal Stromal Tumor Market Outlook, 2018 - 2031

6.1. Asia Pacific Gastrointestinal Stromal Tumor Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Stomach
  - 6.1.1.2. Small Intestine
  - 6.1.1.3. Others
6.2. Asia Pacific Gastrointestinal Stromal Tumor Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Targeted Drug Therapy
  - 6.2.1.2. Chemotherapy
  - 6.2.1.3. Radiation Therapy
  - 6.2.1.4. Surgery
  - 6.2.1.5. Other Therapies
6.3. Asia Pacific Gastrointestinal Stromal Tumor Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Hospitals
  - 6.3.1.2. Clinics
  - 6.3.1.3. Specialized Cancer Treatment Centers
  - 6.3.1.4. Other End Users
6.4. Asia Pacific Gastrointestinal Stromal Tumor Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. China Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.2. China Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.3. China Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.4. Japan Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.5. Japan Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.6. Japan Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.7. South Korea Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.8. South Korea Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.9. South Korea Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.10. India Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.11. India Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.12. India Gastrointestinal Stromal Tumor Market End User, Value (US$Bn), 2018 - 2031
  - 6.4.1.13. Southeast Asia Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.14. Southeast Asia Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.15. Southeast Asia Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.16. Rest of Asia Pacific Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 6.4.1.17. Rest of Asia Pacific Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.18. Rest of Asia Pacific Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Gastrointestinal Stromal Tumor Market Outlook, 2018 - 2031

7.1. Latin America Gastrointestinal Stromal Tumor Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Stomach
  - 7.1.1.2. Small Intestine
  - 7.1.1.3. Others
7.2. Latin America Gastrointestinal Stromal Tumor Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Targeted Drug Therapy
  - 7.2.1.2. Chemotherapy
  - 7.2.1.3. Radiation Therapy
  - 7.2.1.4. Surgery
  - 7.2.1.5. Other Therapies
7.3. Latin America Gastrointestinal Stromal Tumor Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Hospitals
  - 7.3.1.2. Clinics
  - 7.3.1.3. Specialized Cancer Treatment Centers
  - 7.3.1.4. Other End Users
7.4. Latin America Gastrointestinal Stromal Tumor Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Brazil Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 7.4.1.2. Brazil Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 7.4.1.3. Brazil Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 7.4.1.4. Mexico Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 7.4.1.5. Mexico Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 7.4.1.6. Mexico Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 7.4.1.7. Argentina Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 7.4.1.8. Argentina Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 7.4.1.9. Argentina Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 7.4.1.10. Rest of Latin America Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 7.4.1.11. Rest of Latin America Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 7.4.1.12. Rest of Latin America Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Gastrointestinal Stromal Tumor Market Outlook, 2018 - 2031

8.1. Middle East & Africa Gastrointestinal Stromal Tumor Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Stomach
  - 8.1.1.2. Small Intestine
  - 8.1.1.3. Others
8.2. Middle East & Africa Gastrointestinal Stromal Tumor Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Targeted Drug Therapy
  - 8.2.1.2. Chemotherapy
  - 8.2.1.3. Radiation Therapy
  - 8.2.1.4. Surgery
  - 8.2.1.5. Other Therapies
8.3. Middle East & Africa Gastrointestinal Stromal Tumor Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Hospitals
  - 8.3.1.2. Clinics
  - 8.3.1.3. Specialized Cancer Treatment Centers
  - 8.3.1.4. Other End Users
8.4. Middle East & Africa Gastrointestinal Stromal Tumor Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. GCC Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.2. GCC Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.3. GCC Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 8.4.1.4. South Africa Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.5. South Africa Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.6. South Africa Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 8.4.1.7. Egypt Gastrointestinal Stromal Tumor Market by Indication, Value (US$Bn), 2018 - 2031
  - 8.4.1.8. Egypt Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.9. Egypt Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 8.4.1.10. Nigeria Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.11. Nigeria Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.12. Nigeria Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
  - 8.4.1.13. Rest of Middle East & Africa Gastrointestinal Stromal Tumor Market by Indication, Value (US$ Bn), 2018 - 2031
  - 8.4.1.14. Rest of Middle East & Africa Gastrointestinal Stromal Tumor Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.15. Rest of Middle East & Africa Gastrointestinal Stromal Tumor Market End User, Value (US$ Bn), 2018 - 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Indication vs End User Heatmap
9.2. Manufacturer vs End User Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
- 9.5.1. Novartis AG
  - 9.5.1.1. Company Overview
  - 9.5.1.2. Indication Portfolio
  - 9.5.1.3. Financial Overview
  - 9.5.1.4. Business Strategies and Development
- 9.5.2. Sun Pharmaceutical Industries Limited
  - 9.5.2.1. Company Overview
  - 9.5.2.2. Indication Portfolio
  - 9.5.2.3. Financial Overview
  - 9.5.2.4. Business Strategies and Development
- 9.5.3. Pfizer Inc.
  - 9.5.3.1. Company Overview
  - 9.5.3.2. Indication Portfolio
  - 9.5.3.3. Financial Overview
  - 9.5.3.4. Business Strategies and Development
- 9.5.4. Bayer Aktiengesellschaft
  - 9.5.4.1. Company Overview
  - 9.5.4.2. Indication Portfolio
  - 9.5.4.3. Financial Overview
  - 9.5.4.4. Business Strategies and Development
- 9.5.5. NATCO Pharma Limited
  - 9.5.5.1. Company Overview
  - 9.5.5.2. Indication Portfolio
  - 9.5.5.3. Financial Overview
  - 9.5.5.4. Business Strategies and Development
- 9.5.6. Jiangsu Hengrui Medicine
  - 9.5.6.1. Company Overview
  - 9.5.6.2. Indication Portfolio
  - 9.5.6.3. Financial Overview
  - 9.5.6.4. Business Strategies and Development
- 9.5.7. Daiichi Sankyo Company
  - 9.5.7.1. Company Overview
  - 9.5.7.2. Indication Portfolio
  - 9.5.7.3. Financial Overview
  - 9.5.7.4. Business Strategies and Development
- 9.5.8. Cogent Biosciences
  - 9.5.8.1. Company Overview
  - 9.5.8.2. Indication Portfolio
  - 9.5.8.3. Financial Overview
  - 9.5.8.4. Business Strategies and Development
- 9.5.9. Bristol-Myers Squibb
  - 9.5.9.1. Company Overview
  - 9.5.9.2. Indication Portfolio
  - 9.5.9.3. Financial Overview
  - 9.5.9.4. Business Strategies and Development
- 9.5.10. Theseus Pharmaceuticals
  - 9.5.10.1. Company Overview
  - 9.5.10.2. Indication Portfolio
  - 9.5.10.3. Financial Overview
  - 9.5.10.4. Business Strategies and Development
- 9.5.11. Advenchen Laboratories
  - 9.5.11.1. Company Overview
  - 9.5.11.2. Indication Portfolio
  - 9.5.11.3. Financial Overview
  - 9.5.11.4. Business Strategies and Development
- 9.5.12. Ascentage Pharma
  - 9.5.12.1. Company Overview
  - 9.5.12.2. Indication Portfolio
  - 9.5.12.3. Financial Overview
  - 9.5.12.4. Business Strategies and Development
- 9.5.13. Hanmi Pharm.Co.,Ltd.
  - 9.5.13.1. Company Overview
  - 9.5.13.2. Indication Portfolio
  - 9.5.13.3. Financial Overview
  - 9.5.13.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations